1. Home
  2. TNET vs DNTH Comparison

TNET vs DNTH Comparison

Compare TNET & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

N/A

Current Price

$36.12

Market Cap

1.6B

ML Signal

N/A

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

N/A

Current Price

$80.32

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TNET
DNTH
Founded
1988
2015
Country
United States
United States
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2000
2018

Fundamental Metrics

Financial Performance
Metric
TNET
DNTH
Price
$36.12
$80.32
Analyst Decision
Hold
Strong Buy
Analyst Count
6
11
Target Price
$65.80
$119.60
AVG Volume (30 Days)
692.0K
888.6K
Earning Date
05-15-2026
06-01-2026
Dividend Yield
3.04%
N/A
EPS Growth
N/A
N/A
EPS
3.20
N/A
Revenue
$5,010,000,000.00
$2,036,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
$58.85
P/E Ratio
$11.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.67
$13.37
52 Week High
$88.56
$88.45

Technical Indicators

Market Signals
Indicator
TNET
DNTH
Relative Strength Index (RSI) 33.00 76.27
Support Level $33.67 $33.94
Resistance Level $63.28 N/A
Average True Range (ATR) 1.97 4.60
MACD 0.57 3.19
Stochastic Oscillator 43.37 82.54

Price Performance

Historical Comparison
TNET
DNTH

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company providesits services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: